A5020903958- Peripheral Artery Disease Management
- Cardiac Valve Diseases and Treatments
- Cardiac Arrhythmias and Treatments
- Cardiovascular Function and Risk Factors
- Atrial Fibrillation Management and Outcomes
- Cardiac pacing and defibrillation studies
- Cardiac Structural Anomalies and Repair
- Asthma and respiratory diseases
- Heart Failure Treatment and Management
- Inhalation and Respiratory Drug Delivery
- Diabetic Foot Ulcer Assessment and Management
- Mechanical Circulatory Support Devices
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Transplantation: Methods and Outcomes
- Hemodynamic Monitoring and Therapy
- Venous Thromboembolism Diagnosis and Management
- Infective Endocarditis Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Heart Rate Variability and Autonomic Control
- Blood Pressure and Hypertension Studies
- Congenital Heart Disease Studies
- Cardiac Arrest and Resuscitation
- Respiratory and Cough-Related Research
- Drug-Induced Adverse Reactions
- Cardiac electrophysiology and arrhythmias
Ospedale Monaldi
2018-2024
University of Campania "Luigi Vanvitelli"
2019-2021
San Raffaele University of Rome
2019-2020
University of Pisa
1993-2017
Santobono Children's Hospital
2014
Ospedale SS. Annunziata
2007
Azienda Ospedaliera Universitaria Pisana
1999-2006
Fondazione Salvatore Maugeri
1996-1999
McMaster University
1994
Centro Clinico Nemo
1992
Previous studies have suggested that the endogenous release of inhibitory prostanoids limits bronchoconstrictor response to repeated exercise. The aim our study was determine whether inhaled prostaglandin (PG)E2 attenuates exercise-induced bronchoconstriction or methacholine airway responsiveness in asthmatic subjects. Eight subjects with mild stable asthma and exercise were studied on 4 separate days, 48 h apart. Subjects PGE2 placebo a randomized, crossover, double-blind fashion, 30 min...
The number and significance of airway eosinophils in stable COPD is controversial. Aims this study were to evaluate inflammation patients with compared other groups, examine the correlations between inflammatory markers functional indices obstruction. Cellular analysis evaluation eosinophil cationic protein (ECP) levels induced sputum made 46 subjects (10 clinically COPD, 15 asthma, 11 asymptomatic smokers, 10 healthy control subjects). As expected, significantly (p < 0.01) higher asthma...
Microalbuminuria predicts cardiovascular events in diabetic and nondiabetic patients. For a better understanding of the physiopathological importance microalbuminuria atherosclerotic disease, we evaluated relation between urinary albumin excretion arterial blood pressure, left ventricular mass, insulin, lipid levels. The studies were conducted patients with peripheral vascular disease. Urinary (studied by nephelometry; an average triplicate collections from 8 PM to AM), causal...
The COAPT Trial was the first ever to demonstrate a survival benefit in treating functional mitral regurgitation (FMR). That achieved through transcatheter repair selected patients. exact proportion of patients fulfilling selection criteria real-world is unknown.
Background: right ventricle-pulmonary artery (RV-PA) coupling assessed by measuring the tricuspid anular plane systolic excursion (TAPSE)/pulmonary pressure (PASP) ratio has been recently proposed as an early marker of ventricular dysfunction in patients with heart failure a reduced ejection fraction (HFrEF). Methods: As effects sacubitril/valsartan therapy on RV-PA remain unknown, this study aimed to analyse effect drug TAPSE/PASP HFrEF. We retrospectively analysed all outpatients HFrEF...
Diabetes mellitus (DM) is a chronic metabolic disease which independently associated with unfavorable clinical outcomes in patients atrial fibrillation (AF). Few real-world data are available about the performance of non-vitamin K oral anticoagulants (NOACs) among and diabetes. The aim our propensity score-matched cohort study was to compare safety effectiveness Edoxaban versus well-controlled vitamin antagonists (VKAs) therapy this population. In study, we considered AF diabetes on or VKAs...
ABSTRACT Background The COAPT Trial was the first ever to demonstrate a survival benefit in treating functional mitral regurgitation (FMR). That achieved through transcatheter repair selected patient. exact proportion of patients fulfilling selection criteria real-world is unknown. Objectives assess applicability and its impact on patients’ survival. Methods We assessed clinical data follow-up results all consecutive admitted for FMR at our Department between January 2016 May 2021 according...
Functional mitral regurgitation (FMR) is a well-known pathophysiological factor in heart failure (HF) patients, and left atrial function (LAF) novel determinant of clinical status outcome this setting. However, little known about the role FMR on LAF HFrEF patients. Aim study to explore possible interplay between severity with reduce ejection fraction (HFrEF) patients their consequences.We studied 97 consecutive classified two groups: mild-to-moderate MR ore less (FMR group, n = 38)...
Background The worsening of renal function after the start valsartan therapy is relatively common in clinical practice. However, few data are available on incidence beginning with sacubitril/valsartan.Methods We retrospectively enrolled 202 outpatients HFrEF that started sacubitril/valsartan to evaluate prevalence and its significance.Results At 1 month, a (defined as > 20% decrease eGFR occurring month ARNi therapy) was found 68 patients (33%), however mean follow-up 650 ± 80 days,...
Plasma fibrinogen predicts cardiovascular events in patients with stable peripheral arterial occlusive disease, but its predictive value chronic critical limb ischaemia, a condition associated high risk of death, is unknown.A prospective cohort study.Determination and other potential predictors during clinic-based work-up admitted for diagnostic therapeutic evaluation.A total 108 (72 +/- 10 years, 78 males) atherosclerotic disease ischaemia (pain at rest and/or trophic lesions) followed up...
Summary Azelastine, a phthalazinone derivative, is new potent, long acting, orally active anti‐allergic compound with particularly strong H 1 ‐histamine receptor antagonistic effects which has been proven to possess in vitro and vivo number of anti‐inflammatory properties. The aim the present study was investigate whether azelastine would be able prevent and/or reverse seasonal increase non‐specific bronchial responsiveness methacholine pollen allergic patients. Twelve atopic patients (5...